Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Aethlon Medical (TASE:BLWV) Inc . (NASDAQ:AEMD), currently trading at $0.36 with a market capitalization of $7.55 million, will implement a reverse stock split of its common stock at a ratio of 1-for-8. This decision, approved by the company’s board of directors, follows a stockholder vote during a special meeting held on May 13, 2025. The reverse stock split will take effect at 5:00 p.m. Eastern Time on Friday, with trading on a split-adjusted basis commencing on Monday, June 9, 2025, on the Nasdaq Capital Market. According to InvestingPro data, the stock has shown significant volatility, with a beta of 1.88, while maintaining a healthy balance sheet with more cash than debt.
The reverse stock split will consolidate every eight shares of Aethlon Medical’s issued and outstanding common stock into one share. There will be no change in the par value per share. Adjustments will be made to the exercise price and number of shares for outstanding stock options, restricted stock units, and warrants.
No fractional shares will be issued. Stockholders will receive one whole share for any fractional shares resulting from the split. The split will not affect any stockholder’s percentage ownership, except for those receiving additional shares due to rounding.
The new CUSIP number for Aethlon Medical’s common stock post-split will be 00808Y 505. This information is based on a press release statement filed with the Securities and Exchange Commission.
In other recent news, Aethlon Medical Inc . has entered into a warrant inducement agreement, which could expand its investor base and provide additional working capital. The agreement involves the issuance of new unregistered Common Stock Purchase Warrants, allowing the holder to purchase shares at an exercise price of $0.3736 per share. This price is adjustable under certain conditions and the warrants are exercisable six months after issuance, remaining valid for 5.5 years. The transaction has resulted in Aethlon Medical raising approximately $2.316 million before closing costs and agent fees, with plans to use the net proceeds for working capital and other corporate purposes. Concurrently, the company issued about 6.2 million shares of common stock, registered under a Form S-1 registration statement. Aethlon Medical has committed to filing a resale registration statement for the shares underlying the new warrants within 90 days, aiming for effectiveness within 150 days. Maxim Group LLC, acting as the placement agent, will receive a 6.0% cash fee based on the gross proceeds from the warrant exercises, along with reimbursement for legal fees and expenses. This strategic move aims to bolster Aethlon Medical’s financial position and support its ongoing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.